Biotechnology partnerships

CIVD will promote the development of new immunotherapeutic technologies through establishment of collaborative links between its member laboratories and the international biotech industry. CIVD also offers consultancy services and contract research to industry based on the diverse expertise it has available at QIMR Berghofer.

CIVD member laboratories have extensive experience in infectious diseases, cancer therapies, organ transplantation and vaccine testing. CIVD laboratories are equipped with world-class technologies which can provide facilities for both preclinical and clinical testing of novel vaccine formulations. CIVD group leaders are internationally recognised scientists in their fields and are able to provide expert advice on various aspects of vaccine related research and development.

Specific expertise available at CIVD

  • Ex vivo analysis of human and murine immune response
  • Preclinical models for infectious diseases (malaria, Leishmania, EBV, CMV, hookworm, schistosomiasis, scabies, group A streptococcus, Giardia, Trichomonas and Entamoeba), cancer (Hodgkin’s lymphoma, melanoma, nasopharyngeal carcinoma, non-Hodgkin’s lymphoma) and transplantation (stem cell transplant)
  • Bioinformatics and T cell epitope mapping
  • Production of preclinical or clinical grade immunotherapies for infectious diseases and human cancers
  • Expression and production of recombinant proteins and monoclonal antibodies
  • Clinical immune monitoring for vaccine studies
  • Phase I/II/III clinical trial design

New collaborative links with biotech industry

Second collaborative agreement with Henderson Morley
The CIVD has signed another agreement with Henderson-Morley plc for the development of EBV vaccine. The collaborative project will use an EBV polyepitope antigen developed by the team at CIVD, incorporated into the PREPS and L-particles delivery vector, to produce a new vaccine candidate targeted at numerous strains of EBV.
More information

QIMR Berghofer and Merck initiate vaccine research collaboration
In August 2007, researchers from the CIVD at QIMR Berghofer and Merck & Co., Inc., a global pharmaceutical company, have entered into a research collaboration to develop a vaccine to combat Group A Streptococcus (GAS).
More information

Collaborative agreement between Australian Centre for Vaccine Development and Henderson Morley plc
The Directors of Henderson Morley plc, the drug discovery company, are pleased to announce the signature of a material transfer and collaborative research agreement with the QIMR Berghofer Centre for Immunotherapy and Vaccine Development (CIVD), part of QIMR Berghofer Medical Research Institute.
More information

Bookmark and Share